a b s t r a c t (À)-Colchicine, an anti-microtubulin polymerization agent, is a valuable medication and the drug of choice for gout, Behçet's disease and familial Mediterranean fever. It has a narrow therapeutic index due to its high toxicity towards normal cells. Nonetheless, numerous (À)-colchicine derivatives have been synthesized and studied for their structure-activity relationship and preferential toxicity. Different functional groups such as amides, thioamides, N-arylurea and 8,12-diene cyclic have been incorporated into (À)-colchicine, resulting in derivatives (with moieties) that include electron-withdrawing and electron-donating groups. This review article focuses on recent developments in the chemical synthesis of (À)-colchicine derivatives, the substituents used, the functional groups linked to the substituents, the moieties and biological studies. Moreover, the current classification of derivatives based on the (À)-colchicine rings, namely ring A, B, and C (À)-colchicine derivatives, is discussed. This work demonstrates and summarizes the significance of (À)-colchicine derivatives in the biological field, and discusses their promising therapeutics for the future.
an alkaloid originating from the Colchicum autumnale plant [1] . It was first separated in 1820 by Pelletier and Caventou, and later, it was extracted in its pure form in 1883. Since then, (À)-colchicine has been continuously used in the production of amphidiploids and polyploids in plant breeding [2] .
(À)-Colchicine is used in the treatment of different diseases such as cardiovascular disease, recurrent pericarditis, fibrotic disorders and Behcet's disease. In addition, the use of (À)-colchicine for the treatment of arrhythmia and ischemic heart disease is currently being investigated through clinical trials [3, 4] . However, it has been reported to cause kidney and liver failure in patients due to its high toxicity [5, 6] . Nevertheless, (À)-colchicine has also been reported to have an anti-inflammatory effects, which inhibit microtubule polymerization, and obstruct the functioning of neutrophils [7] .
The full chemical name (IUPAC) of (À)-colchicine is N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo [a]heptalen-7-yl]acetamide. Its structure consists of tricyclic-membered rings, namely, ring A, with a trimethoxyl group; ring B, as a sevenmembered ring with a 7-acetamide group; and ring C, which is a tropolonic ring ( Fig. 1) [8, 9] . (À)-Colchicine is available commercially as a light-sensitive, pale yellow powder with a molecular weight of 399.43 g/mol [8] .
However, (À)-colchicine is not suitable for the treatment of cancer due to its high toxicity towards normal cells [10] . It is, therefore, imperative to develop derivatives of (À)-colchicine with increased potency and reduced toxicity that can serve as antitumour/anticancer agents. Over the past decade, several derivatives of (À)-colchicine with reduced toxicity and potential activity have been synthesized as part of structure-activity relationship (SAR) studies. Therefore, this review article evaluated the modifications to the (À)-colchicine rings, the chemical synthesis involved in the preparation of the derivatives, the SAR analysis, and the respective biological applications.
Structure-activity relationship of (¡)-colchicine
Brossi et al. reported on the phenyl-tropolone atropisomerism of colchicine (natural and unnatural). They studied the configurations of colchicine related to bovine brain tubulin binding using NMR analysis and found that the "biaryl" moiety of natural (À)-colchicine exists in the "S"-configuration, while for unnatural (þ)-colchicine, the "biaryl" moiety is in the "R"configuration. In addition, unlike the unnatural (þ)-colchicine with the "R"-configuration, natural (À)-colchicine with the "S"-configuration can bind to tubulin. This specific binding takes place at the hyperhomocysteinemic (CbsT/T) receptor, the interface between the aand b-tubulin due to the methoxy group, which serves as a crucial player for the binding to take place, as revealed by studies into (À)-colchicine binding, where (À)-colchicine analogues, such as (À)-isocolchicine, lack a methoxy group. It has been shown that the binding of (þ)-colchicide to tubulin is ineffective in contrast to that of (À)-colchicine analogues with a methoxy group (Fig. 2) . In vitro and in vivo studies of the treatment of mice infected with L1210 and P388 leukaemia using (À)-colchicine and its analogues showed that (À)-colchicine analogues, such as (À)-thiocolchicine, are able to bind strongly to tubulin owing to the eSCH 3 group and not the eOCH 3 group on the C (10) of its tropolonic ring (Fig. 2 ). On the contrary, (À)-pesudothiocolchicine, which holds an eSCH 3 group at C (9), and (À)-isothiocolchicine, which possesses a eSCH 3 group at C (11), has been shown to have no binding affinity to tubulin. Additionally, the demethylation of the methoxy group on ring A poses a lower toxicity compared to (À)-colchicine. Moreover, the toxicity decreases in the order of the demethylation of the methoxy group; 3-OCH 3 >2-OCH 3 >1-OCH 3 . For the 7-acetamide group, however, any change to C (7) has no impact on the binding and, as such, a variety of groups on C (7) can have an effect on the activity and toxicity of the analogues. Moreover, any group present on C (4) of ring A, such as the aldehyde group, can affect the toxicity, and thus, increase the potency of the compounds. Additionally, the demethylation metabolites of (À)-colchicine have been found to reduce the exposure of animals to hepatotoxicity through the induction of the human gene, locus cytochrome P450 family 3 (CYP3A) compared to (À)-colchicine itself [11e14]. Newlysynthesized (þ)-demecolcinone and (À)metacolchicine analogues of (À)-colchicine using the enantioselective method, have been proven to have a greater potency against A549, MDA-MB-231 and LoVo human cancer cell lines and a lower toxicity than (À)-colchicine ( Fig. 2 ) [15, 16] .
(¡)-Colchicine derivatives
The anti-tumour property of (À)-colchicine is derived from its ability to depolymerize microtubules through the formation of a tubulin-colchicine complex [17] . (À)-Colchicine can be a potential anti-tumour agent if its activity can be improved and, at the same time, its toxicity lowered. This section, therefore, discusses the possibilities of several (À)-colchicine derivatives that have been reported over the past decade [18, 19] .
Ring A (À)-colchicine derivatives
Ring A (À)-colchicine is rich in electrons because of the three methoxy group substituents at C (1), C (2) and C (3), leaving C-4 as the only position that is available for substitution. Reports of substitutions at this position are not extensive because the reactions are difficult to perform since reagents with mild electrophilic properties are required. In addition, a 4-halo-(À)-colchicine synthesis on ring A was reported recently [20] , whereby halogen substituents on (À)-colchicine C-4 (4-flouro-(À)-colchicine, 4chloro-(À)-colchicine, 4-bromo-(À)-colchicine and 4-iodo-(À)-colchicine) were prepared for moderate to high yields by treating (À)-colchicine with NFSI, NCS, NBS and NIS, respectively, under acidic conditions so as to increase the potency and lower the toxicity of (À)-colchicine. Besides halo-(À)-colchicine derivatives, the preparation of several other (À)-colchicine C-4 substituents was also described, and the cytotoxic activity of the new derivatives was studied ( Fig. 3A ) [21] . However, among all these derivatives, only the 4-halo-(À)-colchicine derivatives showed strong activity against human lung adenocarcinoma A549, human colon adenocarcinoma HT29, and human colorectal carcinoma HCT116 cancer cell lines compared to other substituents. Additionally, the 4-halo-(À)-colchicine derivatives possesses a higher selectivity towards HT-29 compared to the other cell lines.
The substitution reaction on C-4 of (À)-colchicine can also take place with the possibility of electrophilic aromatic substitution via the reaction with aldehydes, acids or amide functional groups in an acidic medium [21] . An electrophilic substitution at C-4 of (À)-colchicine at room temperature with formaldehyde in H 2 SO 4 produced the derivative, 4-hydroxymethyl-(À)-colchicine ( Fig. 3B ). Heating to 50 C led to the dimerization of (À)-colchicine with a methylene bridge. Additionally, the use of AcOH resulted in the production of the derivative, 4-acetoxymethyl (À)-colchicine. Under the same conditions in AcOH, (À)-colchicine reacted with an amide to produce the derivative, 4-(acylamino)methyl (À)-colchicine, while it reacted with 4-(trifluoromethyl)benzaldehyde to produce a mixture of stereoisomers (Table 1 ). In terms of biological activity, only the 4-acetoxymethyl (À)-colchicine derivative showed antiproliferative activity towards HL-60 human epidermoid cancer cell lines.
(À)-Colchicine derivatives which are water-soluble have been synthesized ( Table 2 ) [22] . Also, the treatment of 2-demethyl-(À)-colchicine with N,N-dimethylglycine and bis(2-oxo-3-oxazolidinyl)phosphinic chloride in a basic medium resulted in the formation of the derivative, 2-glcinate-(À)-colchicine, which can be converted into salt form via L-tartaric acid in an aqueous medium. Similarly, methylation reactions can take place at position 3 of 2,3-didemethyl-(À)-thiocolchicine via TMSCHN 2 . However, the resulting derivatives have displayed little activity against human lung carcinoma (A549), human ovarian carcinoma (1A9), human epidermoid carcinoma of the nasopharynx (KB), and multi-drugresistant KB subclone expressing P-glycoprotein (KB-V) cancer cell lines. However, 2-O-(N,N-Dimethylglycinyl)-2-demethyl-(À)-thiocolchicine and 2-O-(N,N-Dimethylglycinyl)-2-demethyl-(À)-thiocolchicine tartaric acid salt are more potent in tubulin polymerization than the analogues of (À)-colchicine (Table 3 ).
Ring B (À)-colchicine derivatives
Studies on the structure-activity relationships of (À)-colchicine analogues have demonstrated that ring B is not essential for tubulin binding and hence, antimitotic activity, but it modulates biophysical properties related to kinetics, association rates, activation energy and thermodynamics [7] . However, Ring B derivatives have been shown to enhance immunosuppressant activities using an allogenic mixed-lymphocyte reaction (MLR) assay. A novel immunosuppressant 7-amido-(À)-colchicine derivative was reportedly synthesized through a series of reactions, which included the initial deacetylation of acetamide on C-7 that resulted in the formation of 7-deacetyl-(À)-colchicine (Table 4 ). This was followed by an amidation reaction with an acyl chloride in a basic medium, with the subsequent substitution of the chloride with a nitrate. This, then, resulted in several 7-amido-(À)-colchicine derivatives. In addition, the effects of amide substituents were studied through the methylation of nitrogen on C-7 that was performed with iodomethane in tetahydrofuran (THF). The amide group might have experienced electronic and steric effects following the introduction of a phenyl ring, which had electrons withdrawing and donating substituents to different (À)-colchicine substituents. It has been shown that 7-amido-(À)-colchicine substituents with electrondonating substituents enhance immunosuppressive activity (Table 4 ). In contrast, (À)-colchicine derivatives with electronwithdrawing substituents are potent despite the electronic and steric effects [23] .
Moreover, new colchicine derivatives (KR32160 and KR35345) have been reported as immunosuppressants [24] . T and B cells are lymphocyte cells in the immune system that are activated upon the entry of dangerous external antigens into the body or a Table 1 Structure of position 4 of (À)-colchicine derivatives. Table 2 Structures of positions 2 and 3 of Ring A (À)-colchicine derivatives.
transplanted organ, which is considered as a harmful antigen. The synthesized colchicine derivatives showed an ability to proliferate CD4 þ T-cells and regulate CD8 þ T-cells in rats through the inhibition of tubulin polymerization, the arrest of generation 2 (G2) in cell cycles, the reduced polymerization of mitochondria, and apoptosis ( Fig. 4) . Additionally, these derivatives inhibit the activation of Tcells by obstructing the pathway of STAT3 signalling and IL-2R activation compared to colchicine and traditional immunosuppressant drugs such as cyclosporine A (CsA), which have side effects. Accordingly, the synthesized derivatives have the potential to be considered as novel immunosuppressants.
The conversion of (À)-colchicine to a b-amino alcohol derivative can be performed following treatment with lithium perchlorate and propylene oxide in acetonitrile [19] . The isomers of C-7 amide carbonyl of (À)-colchicine and (À)-isocolchicine derivatives are the oxidized products of the alcohol derivatives using the Swern oxidation reaction. In addition, the effect of the replacement of the amide group with a thioamide group on the (À)-colchicine activity was investigated through the reaction with a thioacetylating reagent, thiobenzimidazolone, with a mixture of deacetyl-(À)-colchicine and deacetyl-(À)-isocolchicine isomers in acetonitrile. The resultant derivatives of these isomers were obtained in high yields. The 7-alkylamine deacetyl-(À)-colchicine and deacetyl-(À)-isocolchicine isomer derivatives were also prepared for the additional investigation of the effect of the amide carbonyl group on the bioactivities of (À)-colchicine ( Fig. 4) . Strong anti-microtubule and cytotoxicity effects against human prostate cancer (PC3) cell lines were evident in all the synthesized derivatives ( Fig. 5 ).
In line with this, the investigation into a series of nitric oxide (NO)-releasing (À)-colchicine derivatives for a more potent antitumor activity was reported. These derivatives were prepared by coupling nitrates with N-methyl (À)-colchiceinamide ( Fig. 6 ) [25] . Nitric oxide is produced in the body by the enzyme, NO synthase, and is involved in physiological roles such as neurotransmission and the immune system. It has been suggested that NO conjugates of cytotoxic agents display selective cytotoxicity for potential antitumour therapy. The SAR study of the NO conjugated colchicines that had been produced showed improved activity compared to Table 3 Ring A (À)-colchicine derivatives antitumor activity in vitro. colchicine (Fig. 6 ). The cytotoxic activity of the N-methyl (À)-colchiceinamide derivatives with 1,3,4-thiadiazole moieties against various cancer cell lines such as human breast carcinoma (MCF-7), human lung cancer (A549), human ovary cancer (A2780) and human hepatoma (BEL7402) cell lines was reported. The SAR study discovered that the position of the substituents on the benzene ring of the benzene alkyl group plays an important role in the activity, where the para-substituted derivatives showed a higher activity than the meta-substituted derivatives. In addition, electronwithdrawing substituent derivatives showed a better activity compared to the ones with electron-donating groups [26] . Nicolaus N. et al. reported on the preparation of a library of triazole (À)-colchicine derivatives involving bioactive C-7 derivatives of (À)-colchicine using 7-azo-7-deacetyl (À)-colchicine as a precursor and Huisgen 1,3-dipolar cycloaddition. This was carried out using click chemistry in the presence of Cu(I) as the catalyst under microwave irradiation. Almost all the (À)-colchicine derivatives inhibited tubulin polymerization, and some of the derivatives targeted the (À)-colchicine binding site in the tubulin competition. The (À)-colchicine rearrangement under reflux in a basic medium produced all colchicine-type derivatives that were less active than colchicinoids [27] .
Another biological study involving a series of 4-chloro-(À)-colchicine derivatives with N-alkanoyl, N-aroyl and hydroxyalkyl groups showed a reduction in the activity of those (À)-colchicine derivatives that possessed longer alkyl chains of amides. However, the potent cytotoxicity was maintained in the cycliccarboxiamide derivative. Notwithstanding the substituent positions, the derivatives of fluorophenyl amide and benzylamide showed good activity. It was shown that methoxy substituents on the benzene ring at the meta and para-positions displayed higher activity than the ortho-position substitution. In contrast to that, substitutions at the meta-position of the nitro substituents posed the highest activity compared to substitutions at the ortho and para-positions, possibly due to the hydrogen bonding interaction of the meta-group at the two positions of the tubulin binding site. Two a-hydroxy alkyl amide derivatives were shown to be potent in vivo for anti-tumour activity [28] .
Recently, new designs of (À)-colchicine derivatives have been characterised by their dual potency, whereby their anti-tumour activity is coupled with the reduction of P-glycoprotein (P-gp) induction [29] . P-gp induction increases multidrug resistance (MDR), thereby inhibiting the effectiveness of chemotherapy. This issue can be surmounted by making N-benzylated colchicine derivatives, which involve substituting the NH-acetyl side chain and replacing 10-OCH 3 with a series of N-linked functionalities (Fig. 7) . This substitution has shown good anti-tumour activity in human colorectal carcinoma (HCT-116) ( Fig. 8 ) and human colon carcinoma (Colo-205) cell lines, whilst displaying a reduction in P-gp induction (Table 5 ). Recently, a new library of N,N 0 -disubstituted urea (À)-colchicine derivatives with an aryl group has been synthesized via substitution reactions using aniline with electron-donating and electronwithdrawing groups. These N,N 0 -disubstituted urea (À)-colchicine derivatives have shown good cytotoxicity that inhibits oncogenes related to telomerase activation and the VEGF/VEGFR-2 autocrine process. Moreover, the presence of an N-arylurea group in (À)-colchicine enhanced its anti-tumour activity compared to an acetyl group. It was observed that N-arylurea substituents with electron-withdrawing groups exhibited higher potency than those with electron-donating groups (Fig. 9 ) [30] .
Ring C (À)-colchicine derivatives
The tropolone moiety representing ring C (À)-colchicine is a structural feature that is crucial for high-affinity binding to tubulin [7] . Ring C derivatives are amenable to prodrug conjugations, and are synthesized with amines and heterocyclic amine substituents at the 10-OCH 3 position of colchicine through an alkylation reaction involving bromoalkylnitrile with cyclic secondary amines. This is followed by a reduction reaction with LiAlH 4 , resulting in racemic and enantiomeric amines. Through the reaction of (À)-colchicine with prepared substituents, high yields of 10-amino-(À)-colchicine can be obtained (Fig. 10) . A biological study showed a high-affinity binding to microtubule polymerization, and the inhibition of DLD-1 colorectal cancer cell lines by amino-(À)-colchicine derivatives owing to reduced entropy [31] .
Huczy nski et al. synthesized 10-amine (À)-colchicine derivatives using different amine substituents following a simple reflux reaction in acetonitrile. Different structures of amine substituents were involved such as saturated and unsaturated alkyl amines and alkyl amines containing oxygen atoms, an aromatic ring and morpholine rings ( Fig. 11 ). Good yields of 10-amine-(À)-colchicine derivatives with a strong inhibition towards various human cancer cell lines (HL-60, HL-60/vinc, LoVo, LoVo/DX and BALAB/3T3) were obtained. The SAR study revealed that the small amine substituent-colchicine derivatives had potent anticancer activities compared to the larger amine substituents (Fig. 11) [18] . Subsequently, the antiproliferative activity of another series of C10-(À)-colchicine derivatives with an N,N 0 -disubstituted aryl group was studied using computational methods [32] . The calculated results of the antimitotic activity from the molecular docking of these derivatives to b-tubulin showed good agreement with the experimental results ( Fig. 12 ). From Fig. 13 , it can be seen that the interactions of (À)-colchicine (compound 1) with Glu 245 and Leu 245 of tubulin were the most important interactions, while the colchicine derivatives had other interaction positions, as shown in Table 6 . Accordingly, the N,N 0disubstituted aryl group showed the effects of steric hindrance posed by the bulky moiety of the substituents, which hampered tubulin binding (as the bonding energy was higher than that of colchicine itself), hence, lowering the antiproliferative activity ( Fig. 13) . Additionally, the C10-amino acid derivatives of (À)-colchicine were prepared following the substitution reaction of the 10-OCH 3 group on ring C with the consistent amines ( Fig. 14) [33].
New (À)-colchicine prodrugs have been synthesized as antiviral agents [34] . These prodrugs contain an ester link substituent, where cleavage occurs by the human enzyme, carboxylesterase-1 (hCE1), which is over-expressed in the immune cells of endothelial, hepatocyte cell and macrophages-monocytic cells. Upon cleavage of the (À)-colchicine prodrugs, the active drug is formed with a high polarity, low permeability of the cell membrane and a shift into the target site for accumulation. Huh-7 cells have shown a lower toxicity and higher activity at the micromolar level for antiviral activity against dengue (DENV) and the Zika (ZiKV) virus.
(À)-Colchicine analogues such as (À)-thiocolchicine, in which the eOCH 3 of C-10 is replaced with eSCH 3 , have been shown to have a stronger inhibition to tubulin polymerization, [ 3 H] (À)-colchicine binding and Burkitt lymphoma cell growth than (þ)-thiocolchicine [35] . In another study, several synthesized (À)-thiocolchicine derivatives displayed reduced cytotoxicity towards cancer cell lines (A549, SK-OV-3, SK-MEL-2, HCT-15 and MCF-7) ( Table 7 ) [36] . (À)-Thiocolchicine derivatives have also been produced via substitution reactions with alkyl nitrates and benzyl nitrates [23] .
A new method of synthesizing 10-(À)-thiocolchicine with alkyl substituents involves the use of excess alkylthiolate salts in water under mild conditions. This method has a short reaction time and produces a high yield (Fig. 15) [37] . High cytotoxic activity has been observed against human cancer cell lines, namely the human DLD-1, LoVo, MCF-7 and MDA-MB-231 cell lines. SAR studies have shown that cytotoxicity is dependent on the length of the alkylthio chain, where the cytotoxicity increases as the chain length decreases. 
Table 5
Cytotoxicity and P-gp induction activities of (À)-colchicine and N-benzylated (À)-colchicine derivatives.
(À)-Colchicine its derivatives a P-gp induction activity b IC 50 In addition, the synthesis of ring C (À)-colchicine derivatives with nitroso and iminonitroso agents was carried out using Diels-Alder cycloaddition reactions, which are highly stereo and regioselective [38] . This was followed by the 8, 12-diene moiety of (À)-colchicine ( Fig. 16 ), in which most derivatives have been shown to be active against the PC-3 and MCF-7 cancer cell lines with the ability to inhibit the (À)-colchicine-tubulin binding in vitro (Table 8 ). These derivatives, therefore, have the potential to be prodrugs following the retro Diels-Alder reactions.
Clinical applications of (¡)-colchicine and its derivatives
As mentioned, (À)-colchicine is used in the treatment of acute gout, familial Mediterranean fever (FMF) and Behcet's disease. The Food and Drug Administration (FDA) of the United States first approved (À)-colchicine in 2009 under the unapproved drugs initiative once its medicinal properties became known [39] . Thus, many studies have been piloted by the use of (À)-colchicine for further applications including liver and heart diseases, and the treatment of tumours [40e42]. Randomized controlled trials (RCTs) have been used to evaluate (À)-colchicine for a wide spectrum of cardiac diseases [43, 44] to study how (À)-colchicine can benefit some cardiac disease patients. The studies showed that there was a reduction in cardiovascular diseases, and (À)-colchicine was able to reduce the rate of post-pericardiotomy syndrome, periprocedural atrial fibrillation and recurrent pericarditis [45] . In addition, (À)-colchicine plays an important role in the prevention of cardiovascular disease by reducing the risk of the formation of cholesterol crystals, while preventing concomitant inflammatory responses through the disruption of neutrophil functions [46] .
Cancer cells are more vulnerable than normal cells to extermination by (À)-colchicine because of the faster rate of mitosis. Hence, many researchers are fascinated by the use of (À)-colchicine and its analogues as anti-tumour drugs due to their antimicrotubule activity. Moreover, (À)-colchicine has a low therapeutic index with a restrained therapeutic value against cancer. Along with the destabilization of microtubuline, the toxicity of (À)-colchicine can cause anaemia, neutropenia, bone marrow damage, and gastrointestinal upset [47e49]. The toxicity of (À)-colchicine limits its clinical applications, while the oral administration of (À)-colchicine is safe when used properly. The probability of using (À)-colchicine concentrations has been clinically studied for the treatment of gastric cancer. The study found that high clinically-acceptable concentrations of (À)-colchicine can be used for the treatment of gastric cancer [50, 51] . The use of (À)-colchicine for the treatment of cancer is possible in clinicallytolerable doses in combination with a self-inhibitor. In addition, some (À)-colchicine derivatives possess anticancer properties [52] . Recently, a study on gout patients showed that (À)-colchicine is significantly capable of reducing the chances of the incidence of cancer in male patients with gout [53, 54] . Additionally, (À)-colchicine and analogues can be used in inactive forms, such as prodrugs and codrugs, which can be activated by enzymes or physiological conditions, in the treatment of cancer [13] . Nevertheless, the use of (À)-colchicine in the clinical treatment of cancer is still being contended. 
Future perspectives
Advancements have been made in the development of modified (À)-colchicine derivatives, particularly involving modifications on rings A and C of (À)-colchicine. Various studies have shown that synthesized (À)-colchicine derivatives that have been biologically evaluated in terms of their anti-tumour properties, have a high potential for clinical use as anticancer agents. The design of novel agents of (À)-colchicine derivatives using substituents should take into account the characteristics of the derivatives, namely their ability to be target-specific, their high affinity for tubulin binding, and their ability to inhibit microtubule polymerization. In addition, the derivatives should increase the efficacy of chemotherapy while reducing multidrug resistance as well as potential side effects. Table 7 Cytotoxic activity for several (À)-thiocolchicine derivatives against cell lines. Gln 245 (backbone donor) and Leu 246 (backbone donor) À7. 50 5 Leu 246 (backbone donor) À6. 17 6 Ala 314 (arene H) and Asn 256 (sidechain acceptor) À8.5
a Based on compound number in Fig. 13 .
Moreover, the possibility of developing water-soluble (À)-colchicine derivatives and using nanotechnology for targeting their delivery into cancer cells without affecting normal cells offer a promising frontier for drug development.
Summary
In summary, (À)-colchicine offers a low therapeutic index in cancer treatment due to its high toxicity towards cancer cells as well as normal cells. Several (À)-colchicine derivatives have been synthesized and tested in terms of their biological activity against many different cancer cell lines in an attempt to reduce unselective cytotoxicity and improve therapeutic activity. Structure-activity relationship studies of these derivatives have shown that electron-donating and/or electron-withdrawing substituents affect the activity of the derivatives, as well as the steric and chain lengths. The potency of the derivatives will increase following replacement of the amide substituent on C-7 of (À)-colchicine with thioamide or thiobenzyl groups. Nitric oxide substituents provide the dual activity of physiological actions and cytotoxicity in cancer therapy. The presence of thiadiazole and triazole moieties on (À)-colchicine derivatives increase the inhibition of tubulin polymerization, as well as compete with the (À)-colchicine itself at the tubulin binding site. Meta-nitro substituents in the benzylamide group increase the activity of (À)-colchicine derivatives up to picomole levels and are able to form hydrogen bonds at the tubulin binding site. The N-benzyl substituent groups on C-10 of the (À)-colchicine derivatives confer a dual potency to the (À)-colchicine derivatives. High stereo-and regioselective derivatives can be obtained through Diels-Alder reactions by using the cycloaddition Fig. 16 . A) Nitroso-(À)-colchicine derivatives. B) Iminonitroso-(À)-colchicine derivatives. of nitroso and iminonitroso agents with an 8,12-diene moiety of (À)-colchicine. This will result in retro Diels-Alder reactions of derivatives that can function as (À)-colchicine prodrugs.
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